| Join ASGT | Contact Us | Site Map | Home |
Membership
| About the Society | |
ASGT HistoryBiographies
David M. Bodine, PhD Dr. Bodine is one of the original members of the American Society of Gene Therapy and was the founding Secretary of the Society from 1996 to 2000. In his capacity as Secretary, he served as Chair of the Abstract Review Committee during those formative years. Dr. Bodine’s laboratory at the National Human Genome Research Institute (NHGRI) investigates the genetics of pluripotent hematopoietic stem cells (PHSCs) to improve the effectiveness of bone marrow transplantation and find better ways to use these unique cells for gene replacement therapy. His major research interests include Stem Cell Gene Therapy, Stem Cell Biology, and Gene Therapy Vector Biology. He hopes to combine what is learned in these areas to develop gene therapy for hemoglobinopathies. Among many awards during his career, Dr. Bodine has received the NIH Quality of Life Award in 1999, the NHGRI Mentor of the Year Award in 2003 and the NIH Mentor of the Year Award in 2004. He is a member of the Publications Committee and Clinical Research Training Institute Awards Committee of the American Society of Hematology. He also serves on the Scientific Advisory Board for the Leukemia and Lymphoma Society. Dr. Bodine presently serves on the Editorial Boards for three different journals: Molecular Therapy, British Journal of Hematology, and Gene Therapy. A PhD graduate of the University of Maine and The Jackson Laboratory in Zoology/Genetics, Dr. Bodine completed his Postdoctoral Fellowship at the Clinical Hematology Branch of the National Heart Lung and Blood Institute, NIH. Dr. Bodine has been on staff at the NHGRI since 1993 and is active on the NHGRI Animal Care and Use Committee (which he chairs), the NIH Animal Research Advisory Committee, the NHGRI Promotion and Tenure Committee, is an NHGRI Transgenic Mouse Core Facility Supervisor (Microinjection), and an NHGRI FACS Core Facility Supervisor.
Kenneth Cornetta, MD Dr. Cornetta's laboratory has been interested in the use and production of clinical grad retroviral and lentiviral vectors. This production facility, as a participant in the NIH sponsored National Gene Vector Laboratory program, has certified over 30 vectors for clinical trials throughout the US. Dr. Cornetta's lab has also conducted clinical trials in the setting of bone marrow transplantation and is currently evaluating optimization of lentiviral constructs for ex vivo and in vivo delivery. Dr. Cornetta has been on staff at Indiana University since 1991 and has previously served in various positions including Associate Professor of Microbiology and Immunology; Director, Hematologic Malignancies Program; Associate Professor of Medicine and of Medical and Molecular Genetics; Director, Adult Bone Marrow and Stem Cell Transplantation Program; Assistant Professor of Medical and Molecular Genetics; and, Assistant Professor of Medicine. Dr. Cornetta has been a member of the ASGT since 1998. Prior to his position of Vice President, he served as the Society's Secretary, and thus, Abstract Chair from 2004-2007 and was a member of the Board of Directors from 2002-2004. He's been the Chair of the Clinical and Regulatory Affairs Committee and the Viral Gene Transfer Vectors Committees, and a member of the Clinical and Regulatory Affairs, Viral Gene Transfer Vectors, Education and Program Committees. Among Dr. Cornetta's career awards and honors are: Council Member, National Center for Research Resources, NIH; American Cancer Society Junior Faculty Award; National Research Service Award Fellowship, NIH; Chief Resident, Department of Medicine, Indiana University; and, New York State Regents Scholarship. Dr. Cornetta received his bachelor's degree from the State University of New York at Albany and his medical degree from Albany Medical College. He completed his residency in Internal Medicine at Indiana University, a fellowship in Gene Therapy at the NHLBI, and a fellowship in Hematology at the University of Wisconsin. Dr. Cornetta's publications include 99 peer reviewed papers and 8 book chapters. He is an Associate Editor of Molecular Therapy, and has also served in editorial capacities for Cancer Gene Therapy, Gene Therapy, Human Gene Therapy, and Proclinica. Other Memberships:
Barrie J. Carter, PhD Dr. Carter is one of the original members of the Society and has served as Secretary (2003-2004, been on the Board of Directors twice (2000-2003 and 2005-2008), and has served in various capacities on the following committees: Publications Committee, Program Committee, Strategic Planning Committee, Abstract Review Committee, Industrial Liaison Committee, and the Bylaws Committee. Dr. Carter has been Executive Vice President and Chief Scientific Officer at Targeted Genetics Corporation in Seattle, Washington since 1992. Previous appointments include Affiliate Professor of Medicine, University of Washington; Chief, Laboratory of Molecular and Cellular Biology, NIDDK, NIH; Head, Macromolecular Genetics Section, Laboratory of Cell Biology, NIDDK, NIH; and Senior Investigator, Laboratory of Experimental Pathology, NIDDK, NIH. During his career, both professional and academic, Dr. Carter has received the GEN Excellence in Biotechnology Award for Outstanding Achievement in Drug Delivery, the Special Achievement Award from the NIDDK, NIH, the New Zealand Institute of Chemistry Prize for Graduate Research, and several awards from New Zealand University. Dr. Carter received his PhD in Biochemistry from the University of Otago in New Zealand, did post-doctoral training at the Imperial Cancer Research Fund in London, UK and was a Visiting Fellow at the Laboratory of Biology of Viruses at the NIAID, NIH. Dr. Carter's major research interests include Gene Therapy, Molecular biology, Virology, Adeno-associated virus, AAV vectors, and Development of gene therapy products.
Arthur W. Nienhuis, MD Dr. Arthur Nienhuis is a full member of the faculty at St. Jude Children's Research Hospitals' Division of Experimental Hematology, having previously served as director and chief executive officer of St. Jude Children's Research Hospital . He is also professor of pediatrics and medicine at the University of Tennessee. Dr. Nienhuis also held the position of chief of the Clinical Hematology and Deputy Clinical Director of the National Institutes of Health's National Heart, Lung and Blood Institute (NHLB). Dr. Nienhuis has published a number of articles in leading scientific journals, including Molecular Therapy, Annals of the New York Academy of Sciences, Gene Therapy, Blood Cells, Molecules and Diseases, Human Gene Therapy, and Cancer Gene Therapy. His current research is focused on genetic therapy of hematological diseases and regulation of disorders that relate to the formation of blood or blood cells. A former vice president of the American Society of Hematology, Dr. Nienhuis served as its president in 1994. He received the Henry M. Stratton Medal from the society for his outstanding body of work in the field of hematology Dr. Nienhuis received his medical degree from the University of California at Los Angeles. |
|
© 2000-2008 All rights reserved.
American Society of Gene Therapy Disclaimer